Uncategorized

RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren’s Syndrome

RemeGen Co. Ltd., a commercial-stage biotechnology company, recently announced significant progress of Telitacicept, that two Phase III clinical trials in China for the treatment of IgA nephropathy and primary Sjögren’s syndrome have completed patient enrollments.

RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren’s Syndrome Read More »

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

Innovent Biologics, Inc. announced that the New Drug Application for IBI311, a recombinant anti-insulin-like growth factor 1 receptor antibody, has been accepted and granted priority review designation by the Center for Drug Evaluation of the China National Drug Administration for the treatment of Thyroid Eye Disease.

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease Read More »

Scroll to Top